These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21079535)

  • 1. Etiology and treatment of overactive bladder in women.
    Shaw HA; Burrows LJ
    South Med J; 2011 Jan; 104(1):34-9. PubMed ID: 21079535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overactive bladder syndrome - management and treatment options.
    Arnold J; McLeod N; Thani-Gasalam R; Rashid P
    Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB).
    El-Zawahry A
    Curr Urol Rep; 2019 May; 20(6):33. PubMed ID: 31098731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial.
    Burgio KL; Goode PS; Johnson TM; Hammontree L; Ouslander JG; Markland AD; Colli J; Vaughan CP; Redden DT
    J Am Geriatr Soc; 2011 Dec; 59(12):2209-16. PubMed ID: 22092152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of OAB in those over age 65.
    Natalin R; Lorenzetti F; Dambros M
    Curr Urol Rep; 2013 Oct; 14(5):379-85. PubMed ID: 23922134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overactive bladder.
    Barkin J
    Can J Urol; 2011 Apr; 18 Suppl():8-13. PubMed ID: 21501545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S; Oo N
    J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overactive bladder: diagnosis and management.
    Robinson D; Cardozo L
    Maturitas; 2012 Feb; 71(2):188-93. PubMed ID: 22197347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of overactive bladder syndrome.
    Srikrishna S; Robinson D; Cardozo L; Vella M
    Postgrad Med J; 2007 Jul; 83(981):481-6. PubMed ID: 17621619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overactive bladder symptoms in women: current concepts in patient management.
    Easton WA
    Can J Urol; 2010 Feb; 17 Suppl 1():12-7. PubMed ID: 20170596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New evidence in the treatment of overactive bladder.
    Brown ET; Martin L; Dmochowski RR
    Curr Opin Obstet Gynecol; 2015 Oct; 27(5):366-72. PubMed ID: 26308197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overactive bladder: treatment options in primary care medicine.
    Sussman DO
    J Am Osteopath Assoc; 2007 Sep; 107(9):379-85. PubMed ID: 17908830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence with antimuscarinic therapy in patients with overactive bladder.
    Haab F; Castro-Diaz D
    Int J Clin Pract; 2005 Aug; 59(8):931-7. PubMed ID: 16033615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The medical management of refractory overactive bladder.
    Robinson D; Giarenis I; Cardozo L
    Maturitas; 2013 Apr; 74(4):386-90. PubMed ID: 23395402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacotherapy of overactive bladder.
    Athanasopoulos A
    Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The medical treatment of overactive bladder, including current and future treatments.
    Athanasopoulos A; Cruz F
    Expert Opin Pharmacother; 2011 May; 12(7):1041-55. PubMed ID: 21299469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.